Astellas Pharma Inc logo

Astellas Pharma Inc - ADR

NEW
OTCPK:ALPMY (Japan)   ADR
$ 10.34 +0.01 (+0.1%) 11:10 PM EST
51.96
P/B:
1.85
Market Cap:
$ 18.49B
Enterprise V:
$ 22.46B
Volume:
172.16K
Avg Vol (2M):
168.05K
Warning! GuruFocus detected 4 Severe warning signs with ALPMY. Try a 7-Day Free Trial to check it out.
Trade In:
Volume:
172.16K
Market Cap $:
18.49B
51.96
Avg Vol (2M):
168.05K
Enterprise Value $:
22.46B
PB Ratio:
1.85
Website SEC Filings Stock PDF
Dataset
Financial Download GuruFocus Premium Icon Manual of Stocksâ„¢

Business Description

Astellas Pharma Inc logo
Astellas Pharma Inc

ISIN : US04623U1025
http://www.astellas.com
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411

Share Class Description:

ALPMY: ADR
Compare
Compare
TSE:4578TSE:4151TSE:4528TSE:4536TSE:4552TSE:4882TSE:4568TSE:4519LLYJNJMRKABBVXSWX:ROGLSE:AZNXSWX:NOVNPFEAMGNXPAR:SANBMYGILD
Traded in other countries / regions
4503.JapanALPMY.USAYPH.Germany4503.Mexico
IPO Date
2008-10-10
Description
Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.

Financial Strength

6/10
Name Current Vs Industry Vs History
Cash-To-Debt 0.36
Equity-to-Asset 0.44
Debt-to-Equity 0.61
Debt-to-EBITDA 3.43
Interest Coverage 3.88
Piotroski F-Score 7/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.83
Distress
Grey
Safe
Beneish M-Score -2.63
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

7/10
Name Current Vs Industry Vs History
3-Year Revenue Growth Rate 9.8
3-Year EBITDA Growth Rate -3
3-Year EPS without NRI Growth Rate -55.4
3-Year FCF Growth Rate -26
3-Year Book Growth Rate 6
Future 3-5Y EPS without NRI Growth Rate Estimate 154.64
Future 3-5Y Total Revenue Growth Rate Estimate 6.94

Momentum Rank

5/10
Name Current Vs Industry Vs History
5-Day RSI 34.48
9-Day RSI 39.06
14-Day RSI 39.28
3-1 Month Momentum % -10.82
6-1 Month Momentum % 12.44
12-1 Month Momentum % -5.64

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.1
Quick Ratio 0.86
Cash Ratio 0.3
Days Inventory 268.02
Days Sales Outstanding 106.95
Days Payable 181.97

Dividend & Buy Back

Name Current Vs Industry Vs History
Dividend Yield % 4.56
Dividend Payout Ratio 2.36
3-Year Dividend Growth Rate 18.6
Forward Dividend Yield % 4.56
5-Year Yield-on-Cost % 8.59
3-Year Average Share Buyback Ratio 1.1
Shareholder Yield % -11.05

Profitability Rank

8/10
Name Current Vs Industry Vs History
Gross Margin % 81.78
Operating Margin % 3.63
Net Margin % 3.09
FCF Margin % 6.97
ROE % 3.49
ROA % 1.57
ROIC % 1.84
3-Year ROIIC % -6.31
ROC (Joel Greenblatt) % 22.42
ROCE % 3.21
Years of Profitability over Past 10-Year 10

GF Value Rank

4/10
Name Current Vs Industry Vs History
PE Ratio 51.96
Forward PE Ratio 27.21
PE Ratio without NRI 52.94
Shiller PE Ratio 19.14
Price-to-Owner-Earnings 37.78
PS Ratio 1.6
PB Ratio 1.85
Price-to-Free-Cash-Flow 23.64
Price-to-Operating-Cash-Flow 14.46
EV-to-EBIT 46.15
EV-to-Forward-EBIT 11.4
EV-to-EBITDA 12.69
EV-to-Forward-EBITDA 9.11
EV-to-Revenue 1.93
EV-to-Forward-Revenue 2.31
EV-to-FCF 28.49
Price-to-GF-Value 0.64
Price-to-Projected-FCF 0.94
Price-to-Median-PS-Value 0.64
Earnings Yield (Greenblatt) % 2.17
FCF Yield % 4.25
Forward Rate of Return (Yacktman) % -0.02

Financials

ALPMY's 30-Y Financials
AAPL
Income Statement Breakdown FY
No Enough Data
AAPL
Balance Sheet Breakdown
No Enough Data
AAPL
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with OTCPK:ALPMY

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Astellas Pharma Inc Executives

Details

GF Value: $16.25

ALPMY

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 11,930.216
EPS (TTM) ($) 0.205
Beta 0.22
3-Year Sharpe Ratio -0.68
3-Year Sortino Ratio -0.89
Volatility % 27.53
14-Day RSI 39.28
14-Day ATR ($) 0.412351
20-Day SMA ($) 10.432575
12-1 Month Momentum % -5.64
52-Week Range ($) 9.15 - 13.14
Shares Outstanding (Mil) 1,789.86

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 7
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Astellas Pharma Inc Filings

Filing Date Document Date Form
No Filing Data

Astellas Pharma Inc Stock Events

Financials Calendars
Event Date Price ($)
No Event Data

Astellas Pharma Inc Frequently Asked Questions

What is Astellas Pharma Inc(ALPMY)'s stock price today?
The current price of ALPMY is $10.34. The 52 week high of ALPMY is $13.14 and 52 week low is $9.15.
When is next earnings date of Astellas Pharma Inc(ALPMY)?
The next earnings date of Astellas Pharma Inc(ALPMY) is .
Does Astellas Pharma Inc(ALPMY) pay dividends? If so, how much?
The  Dividend Yield %  of Astellas Pharma Inc(ALPMY) is 4.56% (As of Today), Highest Dividend Payout Ratio of Astellas Pharma Inc(ALPMY) was 12.12. The lowest was 0.33. And the median was 0.47. The  Forward Dividend Yield % of Astellas Pharma Inc(ALPMY) is 4.56%. For more information regarding to dividend, please check our Dividend Page.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.